Eli Lilly, Junshi Biosciences To Conduct Phase 1 Study In China And US For SARS-CoV-2 Antibody

Eli Lilly and Co. (LLY) announced Monday that its Shanghai-based partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.

from RTT - Biotech https://ift.tt/2Y7p8ZO
via IFTTT